Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1436032 in mIDH1-R132X Advanced AML
NCT03127735Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BAY1436032 in acute myeloid leukemia (AML), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose or Recommended Phase II Dose at 4 weeks and Number of participants with Adverse Events at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
BAY1436032
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03127735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127735.